Eli Lilly Stock-Based Compensation 2010-2025 | LLY

Eli Lilly stock-based compensation for the twelve months ending March 31, 2025 was $1.674B, a 5.32% increase year-over-year.

  • Eli Lilly annual stock-based compensation for 2024 was $0.646B, a 2.72% increase from 2023.
  • Eli Lilly annual stock-based compensation for 2023 was $0.629B, a 69.36% increase from 2022.
  • Eli Lilly annual stock-based compensation for 2022 was $0.371B, a 8.26% increase from 2021.

Eli Lilly Stock-Based Compensation 2010-2025 | LLY

  • Eli Lilly annual stock-based compensation for 2024 was $0.646B, a 2.72% increase from 2023.
  • Eli Lilly annual stock-based compensation for 2023 was $0.629B, a 69.36% increase from 2022.
  • Eli Lilly annual stock-based compensation for 2022 was $0.371B, a 8.26% increase from 2021.
Related Stocks
Company NameMarket
Cap
Johnson & Johnson (JNJ)$377.5B
AbbVie (ABBV)$339.9B
Novo Nordisk (NVO)$307.8B
Roche Holding AG (RHHBY)$258.2B
Novartis AG (NVS)$255.6B
Merck (MRK)$209.3B
Pfizer (PFE)$145.8B
Sanofi (SNY)$119.2B
Bayer (BAYRY)$31.4B
Innoviva (INVA)$1.2B